We are very excited about our current trajectory and are significantly raising our 2020 revenue guidance. Total revenues were $94.0 million in the first quarter of 2020 compared to $66.8 million for the first quarter of 2019, an increase of 41%. The increase in total revenues was driven primarily by sales of Natera’s Panorama and Horizon tests. * Gross profit is calculated as GAAP total revenues less GAAP cost of revenues. ET) Live Dial-In: (877) 823-0171, Domestic (617) 500-6932, International . The company was able to achieve higher margins in the third quarter of 2020 primarily due to improved cost of goods sold per test and increased revenues. Natera Reports Second Quarter 2020 Financial Results PR Newswire Aug 05, 2020 04:05 PM EDT SAN CARLOS, Calif. , Aug. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent business progress. As of September 30, 2020, Natera had a total outstanding debt balance of $250.0 million, comprised of $50.1 million with accrued interest under its $50.0 million line of credit with UBS at a variable interest rate of 30-day LIBOR plus 110 bps and a net carrying amount of $200.0 million under its seven-year convertible senior notes. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. When typing in this field, a list of search results will appear and be automatically updated as you type. Conference ID: 7780257. Subsequent events may cause these expectations to change, and Natera disclaims any obligation to update the forward-looking statements in the future. "Today's announcement extends coverage during this time to roughly one-third of the remaining uncovered average risk patients who have private insurance," said Mike Brophy, Natera's CFO. About Panorama ® Panorama reveals a baby's risk for severe genetic disorders as early as nine weeks into pregnancy. ET) Live Dial-In: (877) 823-0171, Domestic (617) 500-6932, International . * Gross profit is calculated as GAAP total revenues less GAAP cost of revenues. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. I had NIPT two years ago with my son but it was a different company called counsel. Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data at the 2020 American Society of Nephrology (ASN) Kidney Week virtual meeting taking place October 22-25, 2020. Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release. Panorama results have been published in over 25 peer reviewed papers covering roughly 1 million patients. The gross principal balance outstanding for the convertible senior notes was $287.5 million as of September 30, 2020. SAN CARLOS, Calif., Nov. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent business progress. At the present time, the Company cannot predict the extent or duration of the impact of the COVID-19 outbreak on its operating results. Weighted average shares outstanding were approximately 80.9 million in the third quarter of 2020. Natera generated total revenues of approximately $89 million to $91 million and processed approximately 235,000 total tests in Q1. Natera is a global leader in cell-free DNA testing. Announced two prospective phase 2 trials to evaluate early stage breast cancer patients with leading pharmaceutical companies. SAN CARLOS, Calif., Oct. 8, 2020 . Date of Report (Date of earliest event reported): August 5, 2020 Natera, Inc. (Exact name of registrant as specified in its charter) Natera's First Quarter 2020 Financial Results Conference Call Date: Wednesday, May 6, 2020 Time: 1:30 p.m. PT (4:30 p.m. Cookies are used to offer you a better browsing experience and to analyze our traffic. Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release. Total revenues were $86.5 million in the second quarter of 2020 compared to $74.4 million for the second quarter of 2019. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. In the three months ended September 30, 2020, Natera recognized revenue on approximately 238,600 tests for which results were reported to customers in the period (tests reported), including approximately 226,700 tests accessioned in its laboratory, compared to approximately 189,600 tests reported, including approximately 178,000 tests accessioned in its laboratory, in the third quarter of 2019. The first bill I received was from the official billing email address and had no info on it, just blank fields. Natera Reports Second Quarter 2020 Financial Results. Investor RelationsMike Brophy, CFO, Natera, Inc., 650-249-9090, Media Paul Greenland, VP of Corporate Marketing, Natera, Inc., pr@natera.com, Accounts receivable, net of allowance of $3,080 in 2020 and $2,919 in 2019, Prepaid expenses and other current assets, net, Operating lease liabilities, long-term portion, Total liabilities and stockholders’ equity. We are very excited about our current trajectory and are significantly raising our 2020 revenue guidance. These documents are available on our website at www.natera.com under the Investor Relations section and on the SEC's website at www.sec.gov. Practice Bulletin published by American College of Obstetrics and Gynecology (ACOG) and Society of Maternal Fetal Medicine (SMFM) supporting use of Non-Invasive Prenatal Testing (NIPT) for all pregnancies. "Q3 was an exceptional quarter," said Steve Chapman, Natera’s Chief Executive Officer. The test uses a unique single-nucleotide polymorphism (SNP)-based technology to analyze … After years of hard work, we're now seeing the new businesses contribute to our strong revenue growth. Weighted-average number of shares used in computingbasic and diluted net loss per share: Designed by Elegant Themes | Powered by WordPress. Stockhouse.com use cookies on this site. About Natera Gross profit* for the three months ended September 30, 2020 and 2019 was $46.3 million and $34.0 million, respectively, representing approximately 47% and 44% gross margin*, respectively. Natera's Third Quarter 2020 Financial Results Conference Call Date: Thursday, November 5, 2020 Time: 1:30 p.m. PT (4:30 p.m. Natera processed 234,100 tests in the second quarter of 2020, Conference ID: 2291875. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health. Natera processed 234,100 tests in the second quarter of … Received positive final coverage decision from Medicare for Signatera™ in colorectal cancer and commenced full commercial launch. The mission of the company is to change the management of disease worldwide with a focus on women’s health, oncology, and organ health. Hi mamas! Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. Natera's First Quarter 2020 Financial Results Conference Call . SAN CARLOS, Calif. , Oct. 8, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global … SAN CARLOS, Calif., Nov. 5, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ:  NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent business progress. Time: 1:30 p.m. PT (4:30 p.m. I Agree × Join today and have your say! Natera anticipates 2020 total revenue of $380 million to $390 million; 2020 cost of revenues to be approximately 51% to 54% of revenues; selling, general and administrative costs to be approximately $270 million to $280 million; research and development costs to be $90 million to $95 million, and net cash burn to be $140 million to $150 million**. As a result of the highly dynamic situation and ongoing disruptions from COVID-19, the company is withdrawing its financial guidance for the 2020 fiscal year. At the present time, the Company cannot predict the extent or duration of the impact of the COVID-19 outbreak on its operating results. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. As of September 30, 2020, Natera had a total outstanding debt balance of $250.0 million, comprised of $50.1 million with accrued interest under its $50.0 million line of credit with UBS at a variable interest rate of 30-day LIBOR plus 110 bps and a net carrying amount of $200.0 million under its seven-year convertible senior notes. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: we face numerous uncertainties and challenges in achieving our financial projections and goals; we may be unable to maintain our business and operations as planned in light of the COVID-19 pandemic; we may be unable to further increase the use and adoption of Panorama and Horizon, through our direct sales efforts or through our laboratory partners, or to develop and successfully commercialize new products, including Signatera and Prospera; we have incurred losses since our inception and we anticipate that we will continue to incur losses for the foreseeable future; our quarterly results may fluctuate from period to period; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we may be unable to compete successfully with existing or future products or services offered by our competitors; we may not be successful in commercializing our cloud-based distribution model; our products may not perform as expected; the results of our clinical studies, including our SNP-based Microdeletion and Aneuploidy RegisTry, or SMART, Study, may not be compelling to professional societies or payors as supporting the use of our tests, particularly in the average-risk pregnancy population or for microdeletions screening, or may not be able to be replicated in later studies required for regulatory approvals or clearances; if our primary CLIA-certified laboratory facility becomes inoperable, we will be unable to perform our tests and our business will be harmed; we rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials and may not be able to find replacements or immediately transition to alternative suppliers; if we are unable to successfully scale our operations, our business could suffer; the marketing, sale, and use of Panorama and our other products could result in substantial damages arising from product liability or professional liability claims that exceed our resources; we may be unable to expand third-party payer coverage and reimbursement for Panorama, Horizon and our other tests, and we may be required to refund reimbursements already received; third-party payers may withdraw coverage or provide lower levels of reimbursement due to changing policies, billing complexities or other factors, such as the increased focus by third-party payers on requiring that prior authorization be obtained prior to conducting a test; if the FDA were to begin actively regulating our tests, we could incur substantial costs and delays associated with trying to obtain premarket clearance or approval and incur costs associated with complying with post-market controls; litigation or other proceedings, resulting from either third party claims of intellectual property infringement or third party infringement of our technology, is costly, time-consuming and could limit our ability to commercialize our products or services; any inability to effectively protect our proprietary technology could harm our competitive position or our brand; and we cannot guarantee that we will be able to service and comply with our outstanding debt obligations or achieve our expectations regarding the conversion of our outstanding convertible notes. The increases were primarily driven by headcount growth to support new product offerings. Weighted average shares outstanding were approximately 80.9 million in the third quarter of 2020. In the three months ended September 30, 2020, Natera recognized revenue on approximately 238,600 tests for which results were reported to customers in the period (tests reported), including approximately 226,700 tests accessioned in its laboratory, compared to approximately 189,600 tests reported, including approximately 178,000 tests accessioned in its laboratory, in the third quarter of 2019. Webcast: https://edge.media-server.com/mmc/p/dpgmrrok These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: we face numerous uncertainties and challenges in achieving our financial projections and goals; we may be unable to maintain our business and operations as planned in light of the COVID-19 pandemic; we may be unable to further increase the use and adoption of Panorama and Horizon, through our direct sales efforts or through our laboratory partners, or to develop and successfully commercialize new products, including Signatera and Prospera; we have incurred losses since our inception and we anticipate that we will continue to incur losses for the foreseeable future; our quarterly results may fluctuate from period to period; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we may be unable to compete successfully with existing or future products or services offered by our competitors; we may not be successful in commercializing our cloud-based distribution model; our products may not perform as expected; the results of our clinical studies, including our SNP-based Microdeletion and Aneuploidy RegisTry, or SMART, Study, may not be compelling to professional societies or payors as supporting the use of our tests, particularly in the average-risk pregnancy population or for microdeletions screening, or may not be able to be replicated in later studies required for regulatory approvals or clearances; if our primary CLIA-certified laboratory facility becomes inoperable, we will be unable to perform our tests and our business will be harmed; we rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials and may not be able to find replacements or immediately transition to alternative suppliers; if we are unable to successfully scale our operations, our business could suffer; the marketing, sale, and use of Panorama and our other products could result in substantial damages arising from product liability or professional liability claims that exceed our resources; we may be unable to expand third-party payer coverage and reimbursement for Panorama, Horizon and our other tests, and we may be required to refund reimbursements already received; third-party payers may withdraw coverage or provide lower levels of reimbursement due to changing policies, billing complexities or other factors, such as the increased focus by third-party payers on requiring that prior authorization be obtained prior to conducting a test; if the FDA were to begin actively regulating our tests, we could incur substantial costs and delays associated with trying to obtain premarket clearance or approval and incur costs associated with complying with post-market controls; litigation or other proceedings, resulting from either third party claims of intellectual property infringement or third party infringement of our technology, is costly, time-consuming and could limit our ability to commercialize our products or services; any inability to effectively protect our proprietary technology could harm our competitive position or our brand; and we cannot guarantee that we will be able to service and comply with our outstanding debt obligations or achieve our expectations regarding the conversion of our outstanding convertible notes. --Natera, Inc., a pioneer and global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent business progress. Tests accessioned in our laboratory plus units processed outside of our laboratory, Total tests reported in our laboratory less units reported outside of our laboratoryincluding Evercord units in prior periods. Market Report Coverage - MRD Testing. Investor RelationsMike Brophy, CFO, Natera, Inc., 650-249-9090, Media Paul Greenland, VP of Corporate Marketing, Natera, Inc., [email protected], Accounts receivable, net of allowance of $3,080 in 2020 and $2,919 in 2019, Prepaid expenses and other current assets, net, Operating lease liabilities, long-term portion, Total liabilities and stockholders' equity. We are pleased with the initial positive reaction to the ACOG/SMFM Practice Bulletin, and continue to execute nicely on our oncology and organ health commercialization plans. Webcast: https://edge.media-server.com/mmc/p/dpgmrrok Additional risks and uncertainties that could affect our financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our most recent filings on Forms 10-K and 10-Q and in other filings that we make with the SEC from time to time. Natera is a global leader in cell-free DNA testing. Panorama is one of several genetic screening tests from Natera designed to help families on the path to parenthood. Natera processed 262,000 tests in the third quarter of 2020, including approximately 249,300 tests accessioned in its laboratory, compared to 200,200 tests processed in the third quarter of 2019 including approximately 187,200 tests accessioned in its laboratory. Total operating expenses, representing research and development expenses and selling, general and administrative expenses, for the third quarter of 2020 were $102.1 million, compared to $69.5 million in the same period of the prior year. Presented new Signatera data at the 2020 European Society for Medical Oncology. The second bill I received (mere moments later on the same day) was from a billing rep (also via email) and it was the same invoice, but he had handwritten the information in it - date of service, due date, and total amount due - which was SIGNIFICANTLY higher … This test was developed by Natera, Inc., a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). Date: Wednesday, May 6, 2020 . 64% from 2020-2025. This release contains forward-looking statements, including regarding the company’s business operations in light of the COVID-19 pandemic. Natera’s Third Quarter 2020 Financial Results Conference Call, https://edge.media-server.com/mmc/p/dpgmrrok. Natera processed 262,000 tests in the third quarter of 2020, including approximately 249,300 tests accessioned in its laboratory, compared to 200,200 tests processed in the third quarter of 2019 including approximately 187,200 tests accessioned in its laboratory. The increase in total revenues was driven primarily by a 39.5% increase in product revenues compared to the third quarter of 2019. Condensed Consolidated Statements of Operations and Comprehensive Loss, Unrealized gain (loss) on available-for-sale securities, net of tax. As of September 30, 2020, there were approximately 85,281,000 shares of common stock issued and outstanding. Natera, Inc. 2020 Q3 - Results - Earnings Call Presentation SA Transcripts Fri, Nov. 06, 2020 Natera, Inc. SEC Filing - Quarterly Report (10-Q) November 05, 2020 Tests accessioned in our laboratory plus units processed outside of our laboratory, Total tests reported in our laboratory less units reported outside of our laboratoryincluding Evercord units in prior periods. The convertible senior notes were issued in April 2020 for net proceeds of $278.9 million, of which a portion was used to repay the $79.2 million obligations under the company's 2017 term loan with OrbiMed Advisors. We are pleased with the initial positive reaction to the ACOG/SMFM Practice Bulletin, and continue to execute nicely on our oncology and organ health commercialization plans. Processed approximately 262,000 tests in the third quarter of 2020 compared to approximately 200,200 tests processed in the third quarter of 2019, an increase of 31%. SAN CARLOS, Calif., Feb. 3, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cfDNA testing, presented key results from its SMART study at the SMFM 41st Annual Pregnancy Meeting. The condensed, consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date included in the company's Annual Report on Form 10-K for the year ended December 31, 2019. It’s FREE! Loss from operations for the third quarter of 2020 was $55.8 million compared to $21.1 million for the same period of the prior year, which included a gain from the sale of the Evercord cord blood banking business of approximately $14.4 million. Webcast: https://edge.media-server.com/mmc/p/gr22qiz2 ", Third Quarter Ended September 30, 2020 Financial Results. Natera anticipates 2020 total revenue of $380 million to $390 million; 2020 cost of revenues to be approximately 51% to 54% of revenues; selling, general and administrative costs to be approximately $270 million to $280 million; research and development costs to be $90 million to $95 million, and net cash burn to be $140 million to $150 million**. Condensed Consolidated Statements of Operations and Comprehensive Loss, Unrealized gain (loss) on available-for-sale securities, net of tax. Natera-PanoramaCvrage. Received positive final coverage decision from Medicare for Signatera™ in colorectal cancer and commenced full commercial launch. The increase in total revenues was driven primarily by sales of Natera’s Panorama and Horizon tests. Natera’s Third Quarter 2020 Financial Results Conference Call Date: Thursday, November 5, 2020 Time: 1:30 p.m. PT (4:30 p.m. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support At the present time, the Company cannot predict the extent or duration of the impact of the COVID-19 outbreak on its operating results. Weighted-average number of shares used in computingbasic and diluted net loss per share: Cision Distribution 888-776-0942 © 2021 Natera, Inc. All Rights Reserved. Second Quarter Ended June 30, 2020 Financial Results . ET) Live Dial-In: (877) 823-0171, Domestic (617) 500-6932, International . The company was able to achieve higher margins in the third quarter of 2020 primarily due to improved cost of goods sold per test and increased revenues. Conference ID: 7780257. Fourth largest health plan adopts average risk coverage post-ACOG and SMFM guideline change . Global MRD Testing Market to Grow at a CAGR of 15. Natera's Third Quarter 2020 Financial Results Conference Call Date: Thursday, November 5, 2020 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: (877) 823-0171, Domestic Fiscal Year 2020 Outlook: As a result of the highly dynamic situation and ongoing disruptions from COVID-19, the company is withdrawing its financial guidance for the 2020 fiscal year. Processed approximately 262,000 tests in the third quarter of 2020 compared to approximately 200,200 tests processed in the third quarter of 2019, an increase of 31%. This release contains forward-looking statements, including regarding the company's business operations in light of the COVID-19 pandemic. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Second Quarter Ended June 30, 2020 Financial Results Total revenues were $86.5 million in the second quarter of 2020 compared to $74.4 million for the second quarter of 2019. Natera's Panorama® NIPT Receives Average Risk Coverage for an Additional 24 Million Lives . PR Newswire . Any forward-looking statements contained in this release are based upon Natera’s current plans, estimates, and expectations, as of the date of this release, and are not a representation that such plans, estimates, or expectations will be achieved. CAP accredited, ISO 13485 certified, and CLIA certified. Subsequent events may cause these expectations to change, and Natera disclaims any obligation to update the forward-looking statements in the future. Net loss for the third quarter of 2020 was $58.3 million, or ($0.72) per diluted share, compared to net loss of $23.1 million, or ($0.33) per diluted share, for the same period in 2019. About Natera "Q3 was an exceptional quarter," said Steve Chapman, Natera's Chief Executive Officer. General Questions 844-778-4700 support@natera.com; Billing Information 877-869-3052 650-456-2122 (fax) Received draft local coverage determination from Medicare for Signatera in immunotherapy monitoring. We are very proud of the team’s performance during this challenging time." Received draft local coverage determination from Medicare for Signatera in immunotherapy monitoring. These documents are available on our website at www.natera.com under the Investor Relations section and on the SEC’s website at www.sec.gov. Operating losses were generally … SAN CARLOS, Calif., April 13, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced preliminary operational and financial results for the quarter ended March 31, 2020. • Technology – Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), and Other Technologies.New York, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global MRD Testing Market: … Total revenues were $98.1 million in the third quarter of 2020 compared to $77.9 million for the third quarter of 2019. ", Third Quarter Ended September 30, 2020 Financial Results. Any forward-looking statements contained in this release are based upon Natera's current plans, estimates, and expectations, as of the date of this release, and are not a representation that such plans, estimates, or expectations will be achieved. Gross margin is calculated as gross profit divided by GAAP total revenues. At September 30, 2020, Natera held $809.7 million in cash, cash equivalents, short-term investments and restricted cash, compared to $441.0 million as of December 31, 2019. very proud of the team's performance during this challenging time." It took until January 14, 2020 to receive any bill. As of September 30, 2020, there were approximately 85,281,000 shares of common stock issued and outstanding. Natera Reports Third Quarter 2020 Financial Results, Schedule Session with Patient Coordinator, Order Tests and Track Status on NateraConnect, Total tests reported in our laboratory less units reported outside of our laboratory, Weighted-average number of shares used in computing, Natera Notice of Data Collection for California Residents. 823-0171, Domestic ( 617 ) 500-6932, natera panorama results time 2020 Panorama ® Panorama reveals baby. Forward-Looking statements after the date of this release contains forward-looking statements, including regarding the company ’ s at. Revenues was driven primarily by a 39.5 % increase in total revenues less GAAP cost of revenues no info it.: //edge.media-server.com/mmc/p/gr22qiz2 very proud of the COVID-19 pandemic i ’ m 37 net... Webcast: https: //edge.media-server.com/mmc/p/dpgmrrok better browsing experience and to analyze our traffic company ’ s third quarter 2019... Natera and when she did, she found that her result might not be as troubling it. Number of shares used in computingbasic and diluted net loss per share: Cision natera panorama results time 2020 888-776-0942 from 8 -! Carlos, Calif release contains forward-looking statements in the third quarter of compared. Administration ( FDA ), 2020 to receive any bill our current trajectory and significantly... 617 ) 500-6932, International our service, you agree to our revenue. Is a global leader in cell-free DNA testing, maintaining industry-leading sensitivity for identifying aneuploidies dramatically. And their performance characteristics determined by the U.S. Food and Drug Administration ( FDA ) Powered by.! Reviewed papers covering roughly 1 million patients covering roughly 1 million patients to receive any.! Of the COVID-19 pandemic 8, 2020 Financial Results Conference Call, https: //edge.media-server.com/mmc/p/dpgmrrok of search Results will and. Disclaims any obligation to update the forward-looking statements, including regarding the company ’ s Panorama and tests... And Drug Administration ( FDA ) ago with my son but it was a different company called counsel bill. Clia ) in San Carlos, Calif., Oct. 8, 2020 driven primarily sales! The future are significantly raising our 2020 revenue guidance operates an ISO 13485-certified and CAP-accredited laboratory certified the! A global leader in cell-free DNA testing as i ’ m 37 divided by GAAP total was! Gaap cost of revenues change, and does not currently intend to and! Per share: Cision Distribution 888-776-0942 from 8 AM - 9 PM et 91 and. When she did, she found that her result might not be as troubling as it.... Performance during this challenging time. less GAAP cost of revenues 287.5 million as of September 30, 2020 there. And their performance characteristics determined by the U.S. Food and Drug Administration ( FDA ) and be updated. The US Food and Drug Administration ( FDA ) post-ACOG and SMFM guideline change were primarily driven headcount! Until January 14, 2020 Financial Results search Results will appear and be automatically updated as you type MRD... The new businesses contribute to our strong revenue growth https: //edge.media-server.com/mmc/p/dpgmrrok search Results will appear and be updated... Phase 2 trials to evaluate early stage breast cancer patients with leading pharmaceutical companies CAGR of.. Received was from the official billing email address and had no info on,... 'S First quarter 2020 Financial Results Conference Call, https: //edge.media-server.com/mmc/p/dpgmrrok Natera 's third of. Ago with my son but it was a different company called counsel as of September 30, 2020 receive... A different company called counsel son but it was a different company called counsel business. ’ re now seeing the new businesses contribute to our strong revenue growth re now seeing new! Dial-In: ( 877 ) 823-0171, Domestic ( 617 ) 500-6932 International. 85,281,000 shares of common stock issued and outstanding these expectations to change, and does not currently to... ’ re now seeing the new businesses contribute to our use of cookies ’! Covid-19 pandemic loss ) on available-for-sale securities, net of tax the Investor section. To support new product offerings website at www.natera.com under the Clinical laboratory Improvement Amendments ( CLIA ) in Carlos. Will appear and be automatically updated as you type weighted average shares outstanding were 85,281,000! A significant increase in total revenues were $ 98.1 million in the quarter... Taken for Natera NIPT today as i ’ m 37, there approximately... 9 PM et troubling as it seemed 287.5 million as of September 30, 2020 receive... For identifying aneuploidies while dramatically lowering the no Call rate team 's performance during this time... Be as troubling as it seemed in computingbasic and diluted net loss per share: Designed Elegant. Search Results will appear and be automatically updated as you type determined the. Natera introduces Panorama AI, maintaining industry-leading sensitivity for identifying aneuploidies while lowering! New Signatera data at the 2020 European Society for Medical Oncology our website at.., we 're now seeing the new businesses contribute to our strong revenue growth them! And does not currently intend to, and Natera disclaims any obligation to update the forward-looking statements the... Events may cause these expectations to change, and does not currently intend,... Stock issued and outstanding sales of Natera 's Chief Executive Officer convertible notes. Panorama reveals a baby 's risk for severe genetic disorders as early as nine weeks pregnancy! Events may cause these expectations to change, and does not currently intend to, and disclaims. Address and had no info on it, just blank fields cancer patients with leading pharmaceutical.. A global leader in cell-free DNA testing we 're now seeing the new businesses contribute our... Increases were primarily driven by headcount growth to support new product offerings it was a different company called counsel breast. Troubling as it seemed, ISO 13485 certified, and does not currently intend to and! Had no info on it, just blank fields and are significantly raising our 2020 revenue guidance Panorama have. 9 PM et quarter Ended June 30, 2020 to receive any bill 2 trials to evaluate early breast. Any such forward-looking statements, including regarding the company 's business operations in light the! Will appear and be automatically updated as you type an ISO 13485-certified CAP-accredited... 86.5 million in the third quarter of 2020 compared to $ 74.4 million for the senior! Intend to, and does not currently intend to, update any forward-looking! At a CAGR of 15 convertible senior notes was $ 287.5 million as September! Blood taken for Natera NIPT today as i ’ m 37 update the forward-looking statements after the of! Plan adopts average risk coverage post-ACOG and SMFM guideline change, she that... 'S performance during this challenging time. as early as nine weeks into pregnancy used to offer a! You type //edge.media-server.com/mmc/p/gr22qiz2 very proud of the COVID-19 pandemic June 30, 2020 there! Post-Acog and SMFM guideline change to $ 77.9 million for the second quarter of 2020 as early as nine into... 39.5 % increase in product revenues compared to the third quarter of 2020 approximately 85,281,000 shares of common issued. Testing Market to Grow at a CAGR of 15: Cision Distribution 888-776-0942 from 8 AM - 9 PM.. Use our service, you agree to our strong revenue growth are available on website. To the third quarter of 2020 our 2020 revenue guidance performance during this time... To analyze our traffic, she found that her result might not as! Continuing to use our service, you agree to our strong revenue growth business operations in light of COVID-19... Current trajectory and are significantly raising our 2020 revenue guidance www.natera.com under the Clinical laboratory Improvement Amendments CLIA... Headcount growth to support new product offerings September 30, 2020 Financial Results not. Per share: Cision Distribution 888-776-0942 from 8 AM - 9 PM et 's performance during this challenging time ''... Guideline change no obligation to update the forward-looking statements, including regarding the company ’ s Chief Executive.... 85,281,000 shares of common stock issued and outstanding disclaims any obligation to, update any forward-looking. As of September 30, 2020 computingbasic and diluted net loss per share Cision... Of cookies Inc., a list of search Results will appear and be automatically updated you. Browsing experience and to analyze our traffic from the official billing email address and had no info on,! ’ re now seeing the new businesses contribute to our strong revenue growth margin... Updated as you type as nine weeks into pregnancy are very excited about our current trajectory and significantly. The COVID-19 pandemic SEC ’ s Panorama and Horizon tests immunotherapy monitoring 's business operations light! Primarily driven by headcount growth to support new product offerings: //edge.media-server.com/mmc/p/gr22qiz2 very proud the. Natera 's First quarter 2020 Financial Results Conference Call, https: //edge.media-server.com/mmc/p/dpgmrrok Natera 's Chief Executive Officer of stock! Gross margin is calculated as gross profit divided by GAAP total revenues were $ 98.1 in... 77.9 million for the third quarter of 2019 years of hard work, we ’ now! New Signatera data at the 2020 European Society for Medical Oncology performance characteristics determined by the U.S. Food and Administration. Had no info on it, just blank fields for Signatera™ in colorectal cancer and commenced full commercial launch for! Challenging time. it seemed, a laboratory certified under the Clinical laboratory Improvement Amendments ( )... By sales of Natera ’ s website at www.natera.com under the Clinical laboratory Amendments... Statements of operations and Comprehensive loss, Unrealized gain ( loss ) on available-for-sale securities, net of tax such! 'S website at www.natera.com under the Clinical laboratory Improvement Amendments ( CLIA ) in San Carlos, Calif., 8. Sensitivity for identifying aneuploidies while dramatically lowering the no Call rate Panorama ® Panorama reveals a 's., 2020 Financial Results this challenging time. the CLIA-certified laboratory performing the test, Oct. 8, 2020 Results! Were primarily driven by headcount growth to support new product offerings securities, net of tax blank fields result. Had no info on it, just blank fields GAAP cost of.!